Latest @ CSI.

View All
January 26, 2024
CSI Singapore is Proud to Announce the Promotion of Dr. Yvonne Tay to Associate Professor
Dr. Yvonne Tay joined CSI Singapore in 2014 as a Principal Investigator. Since then, she has received multiple awards in recognition of her outstanding research and teaching, including the Yong...
Read More »
January 12, 2024
ASH Abstract Achievement Award 2023 – Irfan Azaman
Irfan Azaman, a Senior Laboratory Executive from Prof. Chng Wee Joo's lab at CSI Singapore, has been selected to receive a 2023 ASH Abstract Achievement Award from The American Society...
Read More »

Press Release

View All
Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025)

Wan-Qin Chong, MBBS a ∙ Jia-Li Low, MBBS a ∙ Joshua K Tay, PhD b,d ∙ Thi Bich Uyen Le, BSca ∙ Grace Shi-Qing Goh, BSc g ∙ Kenneth Sooi, MBBS a ∙ Hui-Lin Teo, MBBS h ∙ Seng-Wee Cheo, MD a ∙ Regina Tong-Xin Wong, BSc g ∙ Jens Samol, MD h,j,k ∙ Ming-Yann Lim, MBBS i ∙ Hao Li, MBBS i ∙ Niranjan Shirgaonkar, MSc l ∙ Shumei Chia, PhD l ∙ Lingzhi Wang, PhD f,g ∙ Anil Gopinathan, MBBS c ∙ Donovan Kum-Chuen Eu, MBBS b ∙ Raymond King-Yin Tsang, MBChB b,d ∙ Prof Kwok-Seng Loh, MBBS b,d ∙ Prof Han-Chong Toh, MBBS m ∙ Nicholas Syn, MBBSe ∙ Li-Ren Kong, PhD f,g ∙ Ramanuj Dasgupta, PhD l ∙ Bee-Choo Tai, PhD n ∙ Yaw-Chyn Lim, PhD …

Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025) Read More »

Follow Us on Twitter

Upcoming Events

View All
×

CSI Web Experience Survey Form

Please Rate Your Satisfaction

Overall Satisfaction For This Site:
Visual Appeal:
Ease Of Finding Information:
Relevance Of Information:
Readability Of Information:
Did you accomplish what you wanted to do today on this site?